1398044-45-5
1398044-45-5
Chemical Structure
Piribedil-d8
Synonym(s): ET-495 d8
- CAS No.: 1398044-45-5
- Formula:C16H10D8N4O2
- Molecular Weight:306.39
IUPAC Name: 2-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl-2,2,3,3,5,5,6,6-d8)pyrimidine
InChIKey: OQDPVLVUJFGPGQ-COMRDEPKSA-N
SMILES: [2H]C1([2H])C([2H])([2H])N(C2=NC=CC=N2)C([2H])([2H])C([2H])([2H])N1CC3=CC(OCO4)=C4C=C3
Biological Activity: Piribedil-d8 is the deuterium labeled Piribedil, which is an antiparkinsonian agent.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Piribedil-d8 | 99.79% | Piribedil-d8 is the deuterium labeled Piribedil, which is an antiparkinsonian agent. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Piribedil (Standard) | ≥98% | Piribedil (Standard) is the analytical standard of Piribedil. This product is intended for research and analytical applications. Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Piribedil-d4 | Piribedil-d4 is the deuterium labeled Piribedil (HY-12707). Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Piribedil | 99.92% | Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
